Thursday, November 12, 2026

Goldman Forecasts 7-Point Big Tech ROE Drop as AI Capex Fails to Deliver Returns

Goldman Sachs has forecast a 7 percentage point decline in Big Tech return on equity, citing AI capital expenditure that has not yet translated to measurable business returns. The bank published an AI spending and profitability report alongside the bearish ROE forecast, signaling institutional concern about the current AI investment cycle. Markets are now pricing in near-term derating of AI infrastructure stocks as margin compression outpaces revenue uplift.

LM Salvado

June 17, 2026

Goldman Forecasts 7-Point Big Tech ROE Drop as AI Capex Fails to Deliver Returns
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Goldman Sachs has forecast a 7 percentage point decline in Big Tech return on equity, attributing the compression to AI capital expenditure that has not yet produced measurable returns.1

The bank released its AI spending and profitability analysis alongside the ROE forecast simultaneously.1 That pairing carries weight. Publishing a bearish equity return projection alongside an AI spending report is an explicit institutional signal that the two are connected — and that the connection is damaging.

Big Tech companies have committed enormous sums to AI infrastructure: data centers, custom silicon, and model development at scale. Goldman's analysis suggests those outlays are front-loaded costs, not yet matched by revenue.1 The result is margin compression that flows directly into equity returns.

Institutional investors are now weighing near-term derating of AI infrastructure stocks.1 Premium valuations built on AI growth narratives become harder to sustain when a major bank quantifies the drag on returns at 7 percentage points.

The pattern has precedent. Large infrastructure buildouts — broadband in the late 1990s, cloud computing in the 2010s — preceded returns by years. AI timelines are more compressed, expectations are higher, and scrutiny of the gap between capital deployment and output is intensifying.

What distinguishes the current moment is institutional weight. Analyst skepticism about AI ROI has circulated since 2024. Goldman's forecast adds a specific number — 7 points of ROE decline — to that skepticism and attaches it to Big Tech as a sector.1

For companies that have used AI infrastructure investment to justify premium multiples, the near-term pressure is to show revenue. Data centers and GPU clusters are depreciating assets. Without measurable output growth, they compress margins quarter by quarter.

Goldman's signal points toward derating as the near-term outcome: investors pricing in margin compression rather than discounting future AI revenue.1 That repricing, if it materializes, would mark a shift from the capital deployment phase of the AI cycle to an accountability phase — where spending requires justification in earnings, not just roadmaps.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com